Drug Targeting
Powered by MPI’s
Universally applicable Drug Response Predictor

MPI’s proprietary drug response predictor (DRP) is unrivalled in efficiency and universality. Predictors have been developed for 59 out of 65 drugs tested.

MPI's patent applied drug response predictor™ is being applied to drugs in the pipeline including anti-cancer drugs. For any drug MPI can predict which disease is most susceptible to a new drug and biologic, and our technology will also predict which patients will respond to the drug at different dose levels. Limiting the clinical trial population to those patients who are predicted to respond to a new drug dramatically increases the probability of successful phase III drug development.

Because the patient selection can be performed both in advance and post-hoc, Drug Targeting Powered by MPI can be used as an insurance against failure. For additional details please see the Powered by MPI brochure in PDF format.

A drug or biologic that has failed in Phase III may with a high probability be rescued by post-hoc application of Drug Targeting Powered by MPI. Numerous options are available in the area of drug rescue ranging from a fee for service to MPI's exclusive licensing and acquisition of a failed anticancer drug.

MPI's patent pending drug response predictor™ is universal and works for 90% of the drugs, biologics and monoclonal antibodies that have been tested so far.

Download "Drug Targeting Powered by MPI brochure"
(This requires Adobe Reader )

Announcements